A vaccine trial was conducted with rhoptry-associated proteins 1 and 2 (RAP1 and RAP2) of Plasmodium falciparum in Saimiri boliviensis monkeys to compare the ability of parasite-derived (PfRAP1 and 2) and recombinant proteins (rRAP1 and 2) to induce protective immune responses and to find adjuvants suitable for use in humans. Eight groups of 6 monkeys each were immunized with parasite-derived or recombinant RAP1 and 2 with Freund's complete adjuvant (FCA) followed by Freund's incomplete adjuvant (FIA), Montanide ISA720 adjuvant, or CRL1005 adjuvant. Recombinant RAP1 and RAP2 were also administered separately, with Montanide ISA720. After 3 immunizations, monkeys were challenged by iv inoculation of 50,000 parasites of the Uganda Palo Alto strain of P. falciparum. Of the animals vaccinated using FCA/FIA, 1 of 6 control monkeys, 3 of 6 immunized with PfRAP1 and 2, and 2 of 6 with rRAP1 and 2 did not require drug treatment. Of the monkeys vaccinated with Montanide ISA720 adjuvant, 0 of the 6 control monkeys, 2 of 6 immunized with RAP1 and 2, 1 of 6 immunized with rRAP1, and 4 of 6 immunized with RAP2 did not require drug treatment. Two of 6 monkeys immunized with PfRAP1 and 2 with CRL1005 did not require treatment. All groups receiving RAP1, RAP2, or both had a significant decrease in initial parasite multiplication rates and there was a significant negative correlation between anti-RAP2 antibody and multiplication rates. Animals were rechallenged with the homologous parasite 126 days after the first challenge. Of the monkeys that did not require drug treatment after the first challenge, none developed detectable parasitemia following rechallenge.
INTRODUCTION
Rhoptry-associated proteins 1 and 2 (RAP1 and RAP2) are located in the rhoptry organelles of Plasmodium falciparum. They form a protein complex and are associated with membranous material discharged from the rhoptries during the process of merozoite invasion. 1 Monoclonal antibodies directed against the complex inhibit parasite growth in vitro. [2] [3] [4] [5] [6] [7] Two vaccine trials in Saimiri sciureus monkeys with RAP1 and RAP2 extracted from parasites using Freund's adjuvants demonstrated that these proteins may induce protective immunity. [8] [9] [10] [11] Monkeys immunized with Plasmodium falciparum parasite-derived RAP1 and RAP2 (PfRAP1 and PfRAP2), isolated by affinity chromatography and further purified by SDS (sodium dodecyl sulfate) polyacrylamide electrophoresis, had substantially lower peak parasitemia when compared to control monkeys and did not require drug treatment.
The genes coding for RAP1 12 and RAP2 11 have been cloned and methods for producing and purifying the corresponding recombinant proteins have been developed. 13, 20 Both recombinant RAP1 (rRAP1) and RAP2 (rRAP2) generate immune responses in mice and rabbits that recognize the native antigens. Human antibodies present in sera from people living in areas endemic for malaria also recognize the rRAP1 and rRAP2. 13, 14 The monkey protection data with PfRAP1 and PfRAP2, the minimal sequence diversity in RAP1 12, 15, 16 or RAP2, 14 and the immunogenicity and antigenicity of the rRAP1 and rRAP2 suggest that these are potential malaria vaccine candidates.
Here we report the results of a study comparing the ability of parasite-derived and recombinant RAP1 and RAP2 pro-teins to induce protective immunity in Saimiri boliviensis. In addition, the results of two adjuvants, Montanide ISA720 17 and a non-ionic block co-polymer CRL1005 18, 19 that have been approved for experimental use in humans, as alternatives to Freund's complete (FCA) and Freund's incomplete (FIA) adjuvant combination used in previous trials, are reported.
involving the animals were under the direction of the resident clinical veterinarian.
Recorded observations on local and/or systemic reactions (e.g., lymphadenopathy, cellulitis, abscesses, necrotizing lesions, arthritis, anorexia, and weight loss) to the candidate vaccine were made at least once a week at the time of blood collection. In the event of a reaction, additional observations were made daily, and supportive treatment instituted.
Preparation of challenge inoculum. Before the trial, studies were made to determine if the Uganda Palo Alto (FUP/Roche) strain of P. falciparum, which was used in the previous study, would produce acceptable levels of parasitemia in S. boliviensis monkeys. Parasites that had been stored frozen for a little over 9 years were obtained as a gift from H. Etlinger (Hoffman-LaRoche, Basil, Switzerland), and passaged into naive monkeys ( Table 1 ). In Passage 1, two monkeys, SI-0774 and SI-2113 supported development of a parasite count in excess of 200,000/L. Monkey SI-0774 died 4 days after the parasite count increased to more than 200,000/L, whereas SI-2113 survived. Because the maximum tolerable parasite count appeared to be slightly in excess of this amount, it was designated as the level at which monkeys in the trial would be routinely treated to ensure their survival. Monkeys SI-0211 and SI-0425 (Passage 3) were injected with 10,000 parasitized erythrocytes from SI-0039. Prepatent periods were 7 and 8 days; however, the parasite count in SI-0211 stabilized below 200,000/L. Monkeys SI-0682 and SI-1179 (Passage 3) were injected with 100,000 parasitized erythrocytes from SI-0039. Prepatent periods were 4 days; both animals developed parasite counts Ͼ 200,000/l on Day 11 and were treated. Monkey SI-1712 (Passage 4) was injected with parasites from SI-1179 that had been stored frozen. The prepatent period was 2 days and on Day 8 the parasite count was 336,000/L. Monkeys SI-1704 and SI-1545 (Passage 5) were injected with 10,000 parasitized erythrocytes from SI-1712; SI-0677 was injected with 100,000 parasitized erythrocytes. At Day 8, blood was collected from AI-1704, diluted in RPMI culture medium, and 50,000 parasitized erythrocytes passaged into each of the 48 monkeys in the immunization trial. Blood from SI-1704 that was frozen at the time of the first challenge was thawed and injected into monkeys SI-2250 and SI-2234. Neither animal developed parasite counts Ͼ 200,000/L. The highest count was in SI-2234; therefore, parasites from this animal were used to rechallenge the immunized animals. Three of the 13 animals in the passage study failed to develop parasite counts Ͼ 200,000/L; each of these had been infected with parasites that had been stored frozen. Based on these limited studies, we decided to challenge the trial animals with 50,000 freshly collected asexual parasites that had been passaged once through a donor animal after being stored frozen.
Experimental protocol. A schematic of the trial ( Figure  1 ) shows 1) immunization at 0, 4, and 8 weeks, 2) first challenge at Week 10, 3) treatment of all animals by Week 18, 4) re-challenge of all remaining animals at Week 28, and 5) termination of the trial at Week 36. Animals were assigned to 8 groups of 6 animals each taking into account sex and weight, using a table of random numbers. Groups received vaccinations as follows: Group 1: FCA/saline emulsion at Week 0, and FIA/saline emulsion at Weeks 4 and 8 (FCA/ FIA control). Group 2: 12.5 g PfRAP1 ϩ 12.5 g PfRAP2 with FCA at Week 0, and similar antigen with FIA at Weeks 4 and 8. Group 3: 12.5 g rRAP1 ϩ 12.5 g rRAP2 with FCA at Week 0 and similar antigen with FIA at Weeks 4 and 8. Group 4: 12.5 g PfRAP1 ϩ 12.5 g PfRAP2 with CRL1005 at Weeks 0, 4, and 8. Group 5: Montanide ISA720/saline emulsion at Weeks 0, 4, and 8 (ISA720 control). Group 6: 12.5 g rRAP1 ϩ 12.5 g rRAP2 with Montanide ISA720 at Weeks 0, 4, and 8. Group 7: 25 g rRAP1 with Montanide ISA720 at Weeks 0, 4, and 8. Group 8: 25 g rRAP2 with Montanide ISA720 at Weeks 0, 4, and 8.
Four criteria of protection were specified in the approved protocol: 1) a decrease in the initial growth rate of parasites; 2) an increase in the time to reach a parasite level requiring treatment (Ͼ 200,000/L); 3) an increase in the proportion not requiring treatment; and 4) a decrease in the maximum parasitemia in the animals not requiring treatment. Note that these criteria apply to the experimental groups, not individual animals.
Immunization schedule. Animals were given 3 immunizations at 4-week intervals (identified as Days 0, 28, and 56). Day 70 (Week 10) was the day of the first challenge. Animals receiving FCA followed by FIA were immunized subcutaneously in 4 sites on the back to facilitate drainage if an ulcer developed. All other animals were immunized intramuscularly in the biceps muscle of the forearm and the quadriceps muscle of the hind legs. The injection sites were shaved to allow visual monitoring for adverse reactions. The animals were examined weekly and reactions at the site of immunization were graded 1ϩ (erythema), 2ϩ (erythema or induration), 3ϩ (erythema and induration), or 4ϩ (ulceration).
The trial was conducted in a blind format. Persons responsible for the reading of blood smears, parasitemia determinations, conduct of serologic testing, collection of specimens, and examination did not know the experimental group to which a monkey had been assigned. To achieve and maintain this level of masking, a person having none of the above responsibilities prepared a code book listing of each animal by its tattooed identification number, its group assignment, and the corresponding treatment group to which each animal had been assigned. The same person was responsible for administering immunizations.
Challenge. Two weeks after the last immunization (Day 70/Week 10), each animal was inoculated with 50,000 parasitized erythrocytes of the FUP/Roche strain of P. falciparum taken from a donor animal (SI-1704), diluted in RPMI 1640 culture medium, and injected intravenously into the femoral vein of each animal. After termination of primary infection, animals were rechallenged with the homologous parasite to determine if there was persistence of immunity. For the rechallenge (Day 196/Week 28), each animal was again injected with 50,000 erythrocytes parasitized with the same strain of P. falciparum from an infected donor animal (SI-2234). Parasite monitoring. After challenge, thick and thin blood films were collected daily and stained with Giemsa by the method of Earle and Perez. 23 Parasite counts were recorded per L of blood. Following the first parasitized erythrocytic challenge, blood films were made and examined from Days 1 through 56 unless the animal had been previously cured of its infection. Following the second challenge, blood films were examined from Days 196-252 (56 days following rechallenge).
When parasite counts exceeded 200,000/L (approximately 5% of the erythrocytes infected), animals were treated orally with 20 mg mefloquine and 50 mg of quinine, which cured their infections. Fifty-six days after infection or reinfection, all untreated infections in animals remaining in the trial were cured by treatment with 20 mg mefloquine. A parasite count of Ͼ 200,000/L was selected for treatment for several reasons. Death of a primate must not be an endpoint in any of our vaccine trials. Our previous experience with P. falciparum infections in New World monkeys has been that some animals may die if their parasitemia is allowed to exceed 10%, and most animals may die or be severely endangered if their parasite count exceeds 20% of the erythrocytes infected. A parasite count of 200,000/L (approximately 5% of erythrocytes infected) was considered an acceptable level that would allow most animals to survive if treated adequately.
Serology. Indirect immunofluorescence assays (IFA) were performed on air-dried blood films of Percol-purified schizonts 24 of the 3D7 cloned P. falciparum line. The films were fixed at Ϫ20ЊC in 10% methanol, 90% acetone. Monkey sera were serially diluted in PBS/5% skim milk powder (1:50, 1: 500, 1:5,000, 1:50,000, and 1:500,000). Five microliters of each dilution was dotted onto slides which were incubated at 4ЊC overnight. Slides were then washed three times with PBS/0.5% Tween 20 (PBS-T) and air dried. Five microliters of specific rabbit serum raised against Saimiri immunoglobulins was added to each well to detect bound antibody; slides were incubated for 2 hours at 37ЊC. After 3 further washes with PBS-T and drying, FITC-labelled goat-anti-rabbit sera (Sigma Chemical Co., St. Louis, MO), diluted 1:100 was added to each well and slides were incubated for 2 hours as previously. Slides were then washed and mounted with 85% Glycerol, 10% 2MTris, 5% w/v n-propyl gallate pH 8.0. Fluorescence was visualized with UV light with a 100ϫ oil immersion objective. Wells were scored as positive when a typical punctate rhoptry staining pattern was visable. The endpoint titer was the reciprocal of the last serum dilution that gave a positive result.
The specificity of antibodies in the sera of immunized animals was determined by Western blotting. Recombinant RAP1 and 2 and Triton X100 extract of whole 3D7 parasites was reduced and then loaded onto 10% SDS PAGE gels and electrophoresed. Protein was electroblotted onto HyBond C Super nitrocellulose membrane (Amersham, United Kingdom), and each membrane was cut into 3 mm wide strips. Each strip contained 50 ng each of rRAP1 and rRAP2 or an approximately equivalent amount of parasite-derived RAP1 and RAP2. Membranes were blocked with PBS/5% skim milk powder for 30 minutes at room temperature. Monkey sera from Weeks 0, 10, and 28 were diluted 1:100 and 1: 500 in PBS/5% skim milk powder and left to bind at 4ЊC overnight. After 3 washes with PBS-T, rabbit-anti-Saimiri Ig serum (prepared as above) was diluted 1:500 and incubated with strips for 2 hours at room temperature. After 3 washes with saline, 10 mM Tris pH 7.4, 0.05% Tween 20, alkaline phosphotase-conjugated goat-anti-rabbit serum (1:3,000) (BioRad Laboratories, Hercules, CA) was added and strips were further incubated for 1 hour at room temperature. Bands were visualized with BCIP/NBT (Promega, Madison, WI) according to the manufacturer's directions. Strips were scored for staining at positions corresponding to RAP1 and/ or RAP2, and on a scale of 0 to 4 for intensity.
Levels of specific antibody in all sera were screened by enzyme-linked immunosorbent assay (ELISA). Briefly, microtiter plates (Greiner Laboratories, Frichenhausen, Germany) were coated with 100 L/well of either rRAP1 or rRAP2 in carbonate bicarbonate buffer (1 g/mL and 3 g/ mL, respectively). Plates were incubated overnight at 4ЊC. Wells were blocked with PBS/1% BSA at room temperature for 1 hour before 3 washes with PBS-T. Test sera (100 L/ well), appropriately diluted in PBS/0.5% BSA, and standard and control sera were added to plates and incubated at room temperature for 2 hours in humid conditions. Plates were then washed as before and specific rabbit-anti-Saimiri serum diluted 1:30,000 was added to all wells and incubated for 1 hour as before. After washing, horseradish peroxidase conjugated, goat-anti-rabbit IgG (BioRad Laboratories) diluted 1:5,000 was added to all wells and plates were incubated for a further 1 hour at room temperature. Plates were washed 3 times and OPD substrate (Sigma Fast, OPD, Sigma Chemical Co.) was added to each well. Plates were allowed to develop in the dark and read at 450 nM using a microtiter plate reader after 1 hour. The working concentrations of all reagents were determined by preliminary titration. Antibody levels were determined in antibody units (RAP1 Ab units or RAP2 Ab units) by comparison with a standard curve made using pooled positive monkey sera. The pooled sera were assigned a concentration in antibody units equal to the interpolated reciprocal dilution that gave an absorbance of 0.1 above background. Test samples were diluted to fall within the range of the standard curve. Control sera were run on each plate to ensure that the standard curves were reproducible between assays.
RESULTS
Parasitemia following challenge. FCA/FIA vaccine groups. Six monkeys were immunized with saline combined with FCA followed by saline and FIA (FCA/FIA control, Group 1). Five of the 6 animals developed parasite counts Ͼ 200,000/L and were treated ( Figure 2A ). Monkey SI-2040 had a maximum parasite count of 120,960/L. The day of maximum parasite count ranged from Day 12 to Day 23 (mean 16.3 days). The accumulated parasite count for the untreated animal over the 56 day observation period was 854,334/L. Thus, despite a maximum parasite count Ͻ 200,000/L, the overall exposure to parasites was considerable.
Three of the 6 animals in the FCA/FIA plus PfRAP1 and PfRAP2 group (Group 2) developed parasite counts Ͼ 200,000/L and were treated ( Figure 2B ). The other three (SI-0824, SI-1001, and SI-2173) were not treated. The day of maximum parasite count for the 6 monkeys ranged from 14 to 23 days (mean 17.8 days). The accumulated parasite counts for the 3 untreated animals were 691,033, 134,173, and 69,987/L, respectively.
Four of the 6 animals in the FCA/FIA plus rRAP1 and rRAP2 group (Group 3) required treatment. Two monkeys (SI-1708 and SI-0705) were not treated ( Figure 2C ). Maximum parasite counts in these animals were 60,300 and 40,500/L, respectively. The day of maximum parasite count for the 6 monkeys ranged from 14 to 24 days (mean 19.5 days). The accumulated parasite counts for the 2 untreated animals were 486,760 and 277,958/L, respectively.
The animals were rechallenged with the homologous parasite 126 days after the primary challenge. Three of the 6 monkeys in the FCA/FIA control group (Group 1), 2 of the remaining 4 monkeys in the FCA/FIA plus PfRAP1 and PfRAP2 group (Group 2), and 2 of the 6 monkeys in the rRAP 1 and rRAP2 group (Group 3) developed patent parasitemia. The 6 animals that failed to develop parasite counts Ͼ 200,000/L following the initial challenge also failed to do so following rechallenge. In addition, 2 animals from the FCA/FIA control group (Group 1) (SI-2142 and SI-2094), and 2 animals from the rRAP1 and rRAP2 group (Group 3) (SI-2124 and SI-2022) failed to develop detectable parasitemia. Parasite counts following rechallenge were greatly reduced, indicating the protective effect of the previous infection with or without immunization.
Montanide ISA720 vaccine groups. All six animals in the ISA720 control group (Group 5) developed parasite counts Ͼ 200,000/L and were treated ( Figure 3A ). The day of maximum parasite count ranged from 11 to 16 days (mean 12.7 days). Four of the six animals in the ISA720 plus rRAP1 and rRAP2 group (Group 6) developed parasite counts Ͼ 200,000/L and were treated ( Figure 3B ). Two monkeys (SI-2165 and SI-2122) had maximum parasite counts of 169,560 and 46,800/L, respectively. The day of maximum parasite count ranged from 11 to 20 days (mean 15.8 days). The accumulated parasite counts for these 2 monkeys were 924,135 and 302,776/L, respectively.
All six animals in the ISA720 plus rRAP1 group (Group 7) developed parasite counts Ͼ 200,000/L and were treated ( Figure 3C ). The day of maximum parasite count ranged from 13 to 16 days (mean 14.8 days).
Two animals in the ISA720 plus rRAP2 group (Group 8) developed parasite counts Ͼ 200,000/L and were treated ( Figure 3D ). The remaining four monkeys (SI-2164, SI-0870, SI-0852, and SI-2176) had maximum parasite counts of 108,000, 101,520, 36,000, and 21,060/L, respectively. The day of maximum parasite count ranged from 13 to 22 days (mean 18.7 days). Following rechallenge, 5 of the 6 ISA720 control animals (Group 5) developed detectable parasitemia. Only monkey SI-1957 was protected. Three of the 6 monkeys in the ISA720 plus rRAP1 and rRAP2 group (Group 6) developed parasitemia; monkey SI-0145 was treated when its parasite count reached 373,680/L. The 2 monkeys that had not been treated following the first challenge did not develop detectable parasitemia following rechallenge. Monkey SI-2125 was also protected from reinfection. Upon rechallenge of the animals immunized with ISA720 plus rRAP1 (Group 7), 4 had parasitemia following rechallenge; two (SI-0673 and SI-0760) did not. The 4 monkeys in the ISA720 plus rRAP2 group (Group 8) that were protected following primary challenge (parasitemia Ͻ 200,000/L) were also protected from rechallenge. The other 2 animals (SI-0864 and SI-2085) developed parasitemia following rechallenge.
CRL1005 vaccine group. Four monkeys (SI-2112, SI-1700, SI-0708, and SI-1925) immunized with CRL1005 plus PfRAP1 and PfRAP2 (Group 4) developed parasite counts Ͼ 200,000/L and were treated (Figure 4 ). Monkeys SI-2181 and SI-1709 had maximum parasite counts of 170,280 and 150,120/L, respectively. The days to maximum parasite count ranged from 12 to 20 days (mean 16.3 days). The accumulated daily parasite counts for these 2 animals were ϭ animals not requiring treatment; ϭ the geometric means of accumulated parasitemia to Day 11 for each group. Numbers above each triangle ϭ the days required to reach a parasitemia of Ͼ 100/L. Numbers below each triangle ϭ the days to peak parasitemia or treatment. 860,760 and 859,125/L, respectively. Following rechallenge, they were protected from infection. Two of the unprotected animals (SI-1700 and SI-1925) were also resistant to reinfection.
Comparison of measures of efficacy. Initial growth rate.
Four measures of initial growth rate were used: 1) Prepatent period; 2) day on which the parasitemia first exceeded 100/ L; 3) parasitemia on Day 11 (the day the first monkey was treated); and 4) cumulative parasitemia up to and including Day 11. The prepatent period was relatively short with 31 of 48 monkeys patent on Day 4 or 5. For most of the monkeys (35/48), only one or two parasites were detected on the first day of patency. Although the average time to Ͼ 100/L for animals immunized with various combinations of RAP1 and RAP2 were greater than the corresponding controls (Figures 2-5 ), (FCA/FIA control: 7.8 days; FCA/FIA ϩ Pf-RAP1/2: 8.3 days; FCA/FIA ϩ rRAP1/2: 8.5 days; ISA720 control: 7.0 days; ISA720 ϩ rRAP1/2: 7.3 days; ISA720 ϩ rRAP1: 7.2 days; ISA720 ϩ rRAP2: 8.3 days; CRL1005 ϩ PfRAP1/2: 7.3 days), there were no significant differences between individual test groups and their corresponding controls, nor was any significant difference detected between all test vaccinated animals and all controls (FCA/FIA and ISA720) (Wilcoxon rank sum test).
Inspection of the daily parasitemia figures indicated some initial synchrony, with parasite density frequently decreasing on every other day. However, a plot of log(parasitemia) or log(cumulative parasitemia) had an approximately exponential increase in parasitemia over this initial period (Figures 2-4) . Therefore, the log(daily parasitemia), or log(cumulative parasitemia) over this period will be approximately proportional to the initial growth rate. The groups of monkeys can only be compared by this method up to the time of the first treatment on Day 11. We chose log(cumulative parasitemia) since this is less affected by the 48-hour periodicity in some monkeys. Figure 5 shows a plot of the cumulative parasitemia to Day 11 plotted on a log scale for the monkeys in each group, together with the geometric mean cumulative parasitemia. The differences between the treatments are significant. Importantly, the two adjuvant control groups gave a highly significant difference in the cumulative parasitemia to Day 11 (FCA/FIA control: 40,000 parasites/L; ISA720 control: 195,170. P ϭ 0.0099, 2 tailed t-test). Consequently, treatment groups were compared only with the corresponding control. As there was no adjuvant control group for CRL1005 containing vaccine, the CRL1005 ϩ PfRAP1/2 group was compared with the ISA720 control group.
With Freund's adjuvants, both PfRAP1/2 (Group 2) and rRAP1/2 (Group 3) gave a significantly reduced cumulative parasitemia to Day 11 compared with the CFA control (P ϭ 0.009 and 0.02, respectively, one tailed t-test), but were not significantly different to each other (P ϭ 0.7, two tailed ttest).
Likewise the treatment groups with ISA720 (rRAP1 ϩ rRAP2 (Group 6), rRAP1 alone (Group 7), and rRAP2 alone (Group 8) all gave significant reductions in the 11 Day cumulative parasitemia (compared to ISA720 control with one tailed t-test P ϭ 0.0099, 0.013, and 0.0095, respectively). Although rRAP2 alone (Group 8) gave the greatest reduction, the differences between the three test groups were not significant (rRAP1/2 vs rRAP1, P ϭ 0.46; rRAP1/2 vs rRAP2 P ϭ 0.46; rRAP1 vs rRAP2, P ϭ 0.19, two-tailed ttest). CRL1005 ϩ PfRAP1/2 (Group 8) also gave a significant reduction in the 11-day cumulative parasitemia compared to the ISA720 control (P ϭ 0.007, one tailed t-test). The ISA720 ϩ rRAP1/2, ISA720 ϩ rRAP2, and CRL1005 ϩ PfRAP1/2 groups had significantly higher variances in the log(cumulative parasitemia) than the ISA720 control (P ϭ 0.05, 0.01, and 0.05, respectively), suggesting that these groups contained responder and nonresponder animals with respect to decreased initial parasite growth.
All measures of initial growth rate were highly correlated. Considering the data from all 48 monkeys as a single group, the Spearman rank correlates of the cumulative parasitemia on Day 11 with prepatent period was rs ϭ Ϫ0.340, P ϭ 0.01; with time to a parasitemia Ͼ 100 L, rs ϭ Ϫ0.570, P Ͻ .0002; and with parasitemia on Day 11, rs ϭ Ϫ0.992, P Ͻ 0.0001.
Increased time to treatment. Because several of the groups had monkeys that did not require treatment, the time to treatment could not be directly compared. Therefore, we compared the time to treatment or to peak parasitemia, but ranking the times to treatment lower than the time to peak parasitemia (e.g., time to treat/peak for animals in the FCA control group were ranked 12, 14, 15, 16, 17, 16 , with the last animal not requiring treatment but with a peak parasitemia on Day 16). All test groups had an increased time to treatment ( Figure 5 ), but only the differences between ISA720 control (Group 5) and ISA720 ϩ rRAP2 (Group 8) and between ISA720 control and CRL1005 ϩ PfRAP1/2 (Group 4) were significant by one tailed Wilcoxon rank sum test (0.025 Ͻ P Ͻ 0.05 for both comparisons). By contrast, when all animals vaccinated with either RAP1, RAP2, or both were compared with all control animals, there was a highly significant increase in the time to treatment/peak parasitemia in the vaccinated animals (P ϭ 0.002, one-tailed, Wilcoxon rank sum). Considering all monkeys as a single group, there was a significant Spearman rank correlation between cumulative parasitemia on day 11 and time to peak/ treatment (rs ϭ Ϫ0.750, P Ͻ 0.0001).
Proportion of animals requiring treatment. With the exception of the ISA720 ϩ rRAP1 group (Group 7), all test groups had more monkeys that did not require treatment than the corresponding control groups. Only the comparison of ISA720 ϩ rRAP2 (Group 8) with its control (i.e., 4/6 com-pared to 0/6 not requiring treatment) was marginally significant (P ϭ 0.0625). When all animals were considered, monkeys that required treatment had a significantly higher cumulative parasitemia on Day 11 than those not requiring treatment (P ϭ 0.005, Wilcoxon rank sum, one-tailed).
Decrease in maximum parasitemia. As the various groups have different combinations of animals treated and nontreated, a direct comparison of peak parasitemia in untreated animals is problematic. Using all animals, we compared each group by assigning treated animals an equal peak parasitemia of 200,000/L. No significant differences were found by Wilcoxon rank sum test for individual test and control groups or for all test compared to all control groups, but once again, considering all animals as a single group, there was a highly significant correlation between the cumulative parasitemia on Day 11 and the peak parasitemia (rs ϭ 0.661, P ϭ Ͻ 0.0001).
Adverse responses. Of the 6 animals receiving FCA/FIC alone, 3 monkeys had 2ϩ responses at the sites of immunization; the other 3 monkeys had no reactions or erythema only. In the group receiving FCA/FIC plus PfRAP1 and PfRAP2 (Group 2), three monkeys had 4ϩ responses at one or more of the sites; one animal had 3ϩ reactions and the other 2 only erythema. One animal died following drug treatment to cure the infection. In the group receiving FCA/ FIA plus rRAP1 and rRAP2 (Group 3), one monkey had 4ϩ reactions, 2 had 3ϩ reactions and the other 3 animals had 2ϩ reactions. None of the reactions was considered severe enough to remove the animals from the trial.
None of the animals immunized with CRL1005 plus rRAP1 and rRAP2 (Group 4) had any adverse reactions nor did animals receiving Montanide ISA720 alone. Of the other animals receiving Montanide ISA720, one monkey in the ISA720 plus rRAP1 and rRAP2 group (Group 6) (SI-2125) had 2ϩ reactions at one site on days 64 through 77, and another (SI-2165) had 1ϩ reactions at one site throughout the study. In the ISA720 plus rRAP1 group (Group 7), one animal (SI-2027) had a 2ϩ reaction at one site on Day 69. In the ISA720 plus rRAP2 group (Group 8), 2 animals (SI-0870 and SI-2164) had 2ϩ reactions at single sites on several occasions.
Serology. Sera from immunized monkeys recognized intact parasites on blood films in IFA. The highest titers were observed in sera from animals that received 1) PfRAP1 and PfRAP2 combined with FCA/FIA (Group 2), 2) rRAP1 and rRAP2 combined with ISA720 (Group 5), and 3) rRAP1 combined with ISA720 (Group 6) ( Table 2 ). The highest scores on Western blot were against rRAP1. Sera from animals that were immunized with rRAP2 also recognized RAP1 on blots ( Table 2) .
By ELISA, all combinations of antigen and adjuvant elicited significant levels of antibody when tested against immunizing antigen ( Table 2 ). Antibody levels peaked by time of challenge and were higher than that of the controls. Interestingly, some animals immunized with RAP1 alone (Group 7) developed significant anti-RAP2 antibody levels in the prechallenge sample. Similarly, some animals immunized with RAP2 alone (Group 8) developed significant antibody levels against RAP1 in the prechallenge sample. A detailed analysis of the fine specificity of the immunologic responses with time will be presented elsewhere (Martin and others, unpublished data).
Correlates of protection. Within the immunized groups, there were substantial variations in the level of antibody produced in individual animals prior to challenge, as well as in the degree of protection as measured by the accumulated parasitemia on Day 11. Because the FCA/FIA control group had a significantly lower accumulated parasitemia on Day 11 than the Montanide ISA720 control, test animals immunized with vaccines containing FCA/FIA were considered separately from animals immunized using CRL1005 or Montanide ISA720. By Spearman rank correlation, there was a significant negative association between anti-RAP2 antibody levels by ELISA in the Montanide ISA720 ϩ CRL1005 group and the accumulated parasitemia on Day 11 (rs ϭ Ϫ0.37, 0.01 Ͻ P Ͻ 0.025). There was no significant association between accumulated parasitemia and ELISA values for RAP1 in the Montanide ISA720 ϩ CRL1005 group, for ELISA values for RAP1 or RAP2 in the FCA/FIA group, or for Western blotting intensities for RAP1 or RAP2 in any group or for IFA scores for any group.
DISCUSSION
This study has several outcomes: 1) the further development of an alternate challenge system for P. falciparum in S. boliviensis monkeys; 2) improved working definitions of efficacy for challenge trials; 3) the demonstration of efficacy for RAP1 and RAP2 using these criteria; and 4) the replacement of FCA/FIA with Montanide ISA720 as a new ''gold standard'' for further development of RAP1/2 vaccines in monkeys.
To allow a direct comparison with the previously obtained protection data of RAP1 and RAP2 in monkeys, 9 in this study we used S. boliviensis and the FUP strain of P. falciparum. Previously, we had established the reproducibility of Aotus nancymai monkeys and the Vietnam Oak Knoll strain of P. falciparum as a preferred model based on the reproducibility of this combination. [25] [26] [27] [28] Based on our pretrial studies, we concluded that challenge parasites for this trial should come from an active infection rather than from frozen stock, and that Ͼ 10,000 parasites would be needed to allow for a rapid increase in parasitemia. Whether all animals injected with this number of parasites would eventually develop parasite counts Ͼ 200,000/L could not be determined based on the data available. However, based on the pretrial results, we believed that the model system was sufficiently suitable to detect a beneficial effect of immunization using the criteria of protection. These conclusions were validated in the subsequent RAP1/RAP2 vaccine trial. In particular, the reproducibility of the parasite growth rates in the Montanide ISA720 control group and the readily detectable decrease in initial growth rates in test groups suggest that the combination of S. boliviensis and the FUP line of P. falciparum will be a potentially useful challenge system for future trials.
The question of appropriate criteria of protection remains unclear. In this study, four criteria were specified in the protocol: a decrease in initial growth rates, an increase in the time to treatment, an increase in the proportion not requiring treatment, and a decrease in the maximum parasitemia in animals not requiring treatment. Four different measures of initial growth rate were examined: increased prepatent period, time to a parasitemia of Ͼ 100/L, parasitemia on Day 11 (the day the first monkey was treated), and the cumulative parasitemia up to and including Day 11. In this study, all four measures were significantly correlated. However, measurement of the prepatent period is subject to considerable relative errors since this period is quite short, and there is a major element of chance in finding a single parasite that defines the start of the patent period, and if missed, a degree of synchrony in the infection accompanied by sequestration of mature parasites means that it is quite likely another 2 days will elapse before parasites are detected. The chance element is reduced with the definition of time to Ͼ 100/L, but the use of both measures of prepatent period measure growth over comparatively few growth cycles, thus minimizing the impact of the vaccine. Measurement of growth over the longest period of approximately expotential increase maximizes the ability to measure the impact on growth. Both the log(parasitemia) and log(cumulative parasitemia) to Day 11 will be approximately proportional to the growth rate during this expotential phase, but the latter may be less sub-ject to fluctuations caused by synchrony of the parasites and the sequestration of mature forms. Thus, we suggest that the log(cumulative parasitemia) up to the last day for which the growth of parasites in all animals in the trial remains approximately expotential should be the most sensitive measure for a vaccine effect.
The difficulty of using time to treatment, the number of animals needing treatment, and the peak parasitemia of animals not requiring treatment is illustrated in the results of this trial. If all of the monkeys in both test and control groups self-cure, or paradoxically, if none of the monkeys in either group self-cure, then measures of time to treatment or maximum parasitemia become approximately equivalent to measures of initial growth and should give similar power to detect a difference between the groups. However, as happened in this trial, where only some animals require treatment, there is ambiguity in ranking the protection in such animals (e.g., should an animal with a peak parasitemia of 121,000/L on Day 16 rank ahead or behind an animal treated on Day 23 at 200,000/L?), and the splitting of the groups makes it difficult to validly apply parametric statistics. Thus, in this situation, there is a major loss of power, and it is not surprising that these criteria failed to find significant differences between the treatment groups with the 6 animals per group used in this trial.
Although perhaps the most appealing endpoint is the proportion of animals treated or not treated, this is clearly the least powerful method of detecting an effect of the vaccine. Even the single comparison between the Montanide ISA720 ϩ rRAP2 group (Group 8) where 4 animals did not require treatment fails to reach statistical significance (P ϭ 0.06256). To give a 90% power of detecting a difference at the 0.05 level of significance when the true values of ''protection'' in the test and control groups are 2/6 and 0/6, respectively, would require approximately 25 animals per group. This number increases substantially if the control group has any animals that spontaneously self-cure below the treatment threshold.
Importantly, when all of the 48 monkeys were considered as a group, all measures of efficacy correlated with the cumulative parasitemia to the day that the first monkey was treated. As it is desirable to avoid using multiple measures of efficacy since the multiple comparisons needed are likely to give apparent significance by chance, use of this method, or the very closely related parasitemia on the day the first monkey is treated, is likely to give the best power of detecting efficacy, without risking missing effects detected by other measures. Similar conclusions have been reached in analysing the results of studies of malaria vaccine efficacy in model studies in mice. 29 In this study, we have confirmed that vaccines containing RAP1 and RAP2 stimulate immunity in S. boliviensis monkeys. As judged by their ability to decrease the growth of parasites over the first 11 days of infection, a mixture of recombinant RAP1 and RAP2 were as effective as parasitederived RAP1 and RAP2 with FCA/FIA. With Montanide ISA720 adjuvant, rRAP2 was more effective than rRAP1, and the mixture was as effective as RAP2 alone, suggesting that RAP2 was the major active component in the mixture. This conslusion is further strengthened by the significant Spearman rank correlation between the anti-RAP2 titers measured by ELISA and the accumulated parasitemia to Day 11.
Whether RAP1 has any efficacy at all in this system is not clear. There was a significant decrease in the accumulated parasitemia to day 11 in the groups receiving rRAP1 alone with Montanide ISA720 when compared to the Montanide ISA720 control. However, monkeys immunized with RAP1 alone made detectable antibodies against RAP2. Although RAP1 and RAP2 share no significant sequence homology, this observation is consistent with earlier reports that RAP1 stimulated anti-RAP2 antibody in mice and vice versa. 13, 30 It is interesting that within the rRAP1/ISA720 monkey group, the three monkeys with the lowest RAP2 antibody level had the highest accumulated parasitemia, and the three monkeys with the highest RAP2 titers had the lowest accumulated parasitemia.
Full-length recombinant RAP1 was expressed at very low levels in the E. coli system, and therefore, the form used in this and other studies represents a truncated form of the molecule consisting of amino acids 23 to 608. 13 Protective epitopes on RAP1 may not have been available due to conformational or amino acid differences in the recombinant form. Further work on the expression of RAP1 is required before its full potential as a vaccine candidate can be determined.
Consideration of the antibody kinetics and the parasite levels on the initial challenge and rechallenge again suggests that there are multiple effector mechanisms responsible for parasite clearance during the initial challenge and for sterile immunity in the rechallenge. We suggest that the effect of vaccination with RAP1 and RAP2 has been to slow the initial growth of parasites sufficiently to enable other immune responses to occur that then lead to parasite clearance. All 14 of the animals that did not require drug treatment in the first challenge failed to develop parasitemia in the second challenge compared with only 10 of the surviving 34 animals that were treated. Therefore, the induction of this secondary response cannot be simply proportional to parasite load, since the monkeys that were not treated had the lowest total accumulated parasite load.
Interestingly, 3 of the monkeys that cleared their initial infection and were immune to rechallenge, developed a recrudescence around 7 weeks after the initial challenge. Such a pattern suggests that immunity against a variant antigen such as PfEMP1 may be important in this phenomenon since both the challenge inocula would share the same variant antigen-type specificities, but not the recrudescent parasitemia.
An important issue in the development of a vaccine is the choice of adjuvant. Although Freund's complete and incomplete adjuvants have been widely used in vaccine development, these adjuvants are unacceptable for humans. In this study, the justification for RAP1 and RAP2 as a vaccine candidate was based on the results with FCA/FIA; it was important to inlude monkeys vaccinated with FCA/FIA to compare the potency of other more useful adjuvants. The use of Freund's adjuvant resulted in adverse reactions at the immunization sites in some of the animals, especially in the animals receiving FCA/FIA and antigen combinations. However, in this trial, none was considered severe enough by the attending veterinarian to remove the animals from the study.
In addition to the potential complications with adverse reactions, the use of FCA/FIA alone resulted in significantly reduced initial growth compared with the Montanide ISA720 control group. Similar effects have been seen in previous trials in animals receiving Freund's adjuvant alone. 25 FCA had been shown to cause non-specific immune activation, and this may be responsible for one of the unimmunized animals receiving FCA/FIA being able to control its infection with a maximum parasitemia of less than 200,000/L. The adjuvant effect makes the effect of the antigen more difficult to assess, but the proportional decrease in initial growth rates of the RAP1/2 ϩ FCA/FIA groups compared to the FCA/FIA control is similar to the proportional decrease seen in the RAP1/2 and RAP2 ϩ ISA720 groups suggesting that the incremental effects of including antigen was similar for the FCA/FIA and Montanide ISA720 formulations.
Previous studies in this laboratory have employed the non-ionic block co-polymer P1005. [31] [32] [33] [34] This is a high molecular weight block co-polymer (ϳ10,000 Da), and was emulsified with oil in water preparations containing other immune modifiers. These vaccines elicited significant levels of protection, with relatively minor adverse reactions in rhesus and Saimiri monkeys. The CRL1005 adjuvant used in this study is the polymer component of the P1005 and is not emulsified in oil. These high molecular weight polymers are soluble in aqueous buffers and form micro-particles that incorporate proteins. 19 These particles are thought to alter the route and rate of antigen uptake and to provide a carriermediated adjuvant effect. CRL1005 stimlated significant production of IgG1 and IgG2b, but only low levels of IgG2a in mice, indicating stimulation of both type 1 and type 2 lymphocyte subsets. 18 The mode of action of CRL1005 is therefore probably quite different from that of the depot-type oil emulsion adjuvants FCA/FIA and the Montanide ISA720. In this study, CRL1005 stimulated lower levels of antibody than either of the oil based formulations ( Table 2) .
Because of constraints on the availability of monkeys, we were unable to include a CRL1005 control group and therefore have compared the parasitologic results from this group to the Montanide ISA720 control. However, although there was a poor immune response against both RAP1 and RAP2, two of the 6 animals were able to control their infections, suggesting that the control of infection in these animals may be due to an adjuvant effect. Further studies will need to be done, including the use of appropriate control groups to establish if the decreased initial growth rate and the ability of 2 monkeys to control their infection is due to immunity induced by RAP1 and RAP2.
The results obtained with Montanide ISA720 plus rRAP2 are encouraging. Montanide ISA720, a metabolisable oil preparation, has been successful in primate studies of other malaria vaccine candidates, 35 and has been used in phase 1 and 2 human clinical trials of malaria vaccines. 17, 36 Thus, this combination is showing promise for human vaccine trials. Furthermore, this combination can now be used to replace RAP1 and RAP2 with FCA/FIA as a standard in monkeys for screening a larger panel of adjuvants and other variables to find optimum formulations and for studies to elucidate the mediators of protection. maintaining the masking. We also thank Darrin Taylor for assisting with performing the serology. 
